Breathing in is a muscular pull that makes space for air; breathing out at rest is just letting that space collapse back down.

Breathing in (inspiration) — this one takes muscle work:

Two muscles do the work: your diaphragm (the dome-shaped muscle under your lungs) CONTRACTS and flattens downward, and the external intercostal muscles between your ribs lift the rib cage up and out. Both movements make the chest cavity bigger — thoracic volume INCREASES. Think of the lungs like a bellows stretched inside a bigger box: when the box gets bigger, the pressure inside the lungs drops (intrapulmonary pressure DECREASES) below the pressure of the air outside your body. Air always moves from high pressure to low pressure, so air flows IN to equalize things. That's why inspiration is called 'active' — it requires muscles doing work.

Breathing out at rest (expiration) — this one is passive:

The diaphragm simply RELAXES and floats back up, the ribs drop back down, and the chest cavity shrinks — thoracic volume DECREASES. A smaller box squeezes the air inside, so intrapulmonary pressure INCREASES above the pressure outside, and air gets pushed OUT. No extra muscle contraction is needed at rest — it's elastic recoil, like letting go of a stretched balloon.

Gas exchange — why oxygen and carbon dioxide swap places:

Oxygen diffuses out of the air-filled alveoli and into the blood in the surrounding capillaries; carbon dioxide diffuses the opposite way, out of the capillaries and into the alveoli to be exhaled. Both moves follow the same simple rule: gas moves from HIGH pressure/concentration to LOW pressure/concentration. This is simple diffusion — it doesn't cost the body any energy, it just happens because of the pressure difference.

Two zones of the airway — one moves air, one trades gas:

What the alveoli (the tiny air sacs) actually do — four jobs:

1. Gas exchange — the main event, described above.
2. Make SURFACTANT — a slippery substance produced by TYPE II PNEUMOCYTES (a specific alveolar cell type) that reduces surface tension inside the alveoli, so they don't stick shut and collapse like a wet balloon.
3. Defend the lungs — macrophages living in the alveoli eat debris and pathogens.
4. Provide a dense capillary network — lots of tiny blood vessels wrapped around the alveoli, maximizing the surface area for gas exchange.

Obstructive disease means the airway is narrowed so air struggles to get OUT; restrictive disease means the lung itself can't expand, so air struggles to get IN.

Everything else about these two categories follows from that one difference. Picture obstructive disease as a narrowed drinking straw — the passage is blocked or floppy, so it's hard to push air through it, especially breathing OUT, since exhaling depends on that passage staying open as pressure inside pushes air out. Picture restrictive disease as a lung wrapped in something stiff — the tissue itself won't stretch, so it's hard to pull air IN, no matter how open the airways are.

Three measurements, each building on the last:

• FVC (forced vital capacity) — the total volume you can forcibly exhale. To measure it: inhale as much as you possibly can, then exhale as long and as forcefully as possible.
• FEV1 — the volume you exhale in just the FIRST SECOND of that same forceful exhale.
• FEV1/FVC ratio — how much of your total air you can push out in one second. This ratio is THE DIAGNOSTIC DISCRIMINATOR that tells obstructive and restrictive disease apart.

Here's why the ratio works the way it does, tying back to the core distinction: in obstructive disease, the airway itself is narrowed, so air is slow to get OUT — you can eventually blow out a decent total volume, but not quickly, so FEV1 drops much more than FVC does, and the ratio falls BELOW 70%. In restrictive disease, the lung can't expand, so the total volume (FVC) is small from the start — but whatever air is in there comes out at a normal rate, so the ratio stays normal or even goes above 70%.

Bronchodilator response (reversibility) — does a rescue inhaler fix the problem?

Give a bronchodilator and re-test. If FEV1 improves by 12% AND by 200 mL or more, that's a significant response — meaning the narrowing was at least partly reversible, which is consistent with ASTHMA. COPD, by contrast, is defined by a POST-bronchodilator FEV1/FVC that's still below 0.70 — the narrowing is fixed and irreversible, the inhaler doesn't undo it.

Chronic bronchitis is chronic inflammation and mucus overload IN the airways themselves — the pipes get clogged and thickened, but the air sacs at the end are still intact.

How it develops, step by step:

It starts as an INFLAMMATORY process in the BRONCHI AND BRONCHIOLES. Chronic irritation causes the mucus-making goblet cells to grow bigger and more numerous — HYPERTROPHY AND HYPERPLASIA — so they oversecrete mucus. At the same time, the lining changes type — epithelial METAPLASIA — swapping out the normal ciliated columnar cells (which have tiny hairs that sweep mucus up and out) for non-ciliated squamous cells that can't sweep at all, so mucus can no longer be cleared. White blood cells migrate in, and the bronchial wall itself undergoes FIBROSIS AND THICKENING. Put it together — more mucus, no way to clear it, thicker walls — and the result is airway narrowing.

Signs and symptoms:

The classic sign is a PERSISTENT PRODUCTIVE COUGH, along with excessive sputum. Dyspnea (shortness of breath) is present, especially during exacerbations. CYANOSIS (a bluish skin tone from low oxygen) is common, along with wheezing, frequent respiratory infections (because stagnant mucus is a breeding ground for infection), and peripheral edema. This combination — overweight and cyanotic — earns the nickname the "BLUE BLOATER."

The lab finding that distinguishes it from emphysema:

DLCO (a measure of how well gas actually crosses into the blood) is NORMAL or only mildly reduced — 80% or above. That's because the problem here is airway obstruction, not destruction — the actual gas-exchange surface at the alveoli is still intact.

Treatment:

• Smoking cessation
• Bronchodilators (LABA + LAMA — long-acting beta-agonist plus long-acting muscarinic antagonist)
• Inhaled corticosteroids in selected patients
• Antibiotics for infectious exacerbations
• Vaccinations
• Pulmonary rehabilitation
• Oxygen therapy targeting 88–92%
• Airway clearance techniques

Emphysema is the opposite problem from chronic bronchitis: instead of clogged pipes, the air sacs themselves are being destroyed.

How it develops, step by step:

It's a DESTRUCTIVE process in the ALVEOLI. Normally, an enzyme called elastase (which breaks down tissue) is kept in check by antiprotease defenses. When that balance tips — a protease/antiprotease imbalance — ELASTASE is left free to break down the elastic fibers that give lung tissue its springiness. That causes alveolar wall destruction and a LOSS OF ELASTIC RECOIL. Without that spring-back, the airways collapse when you try to exhale, which traps air behind them — AIR TRAPPING — and over time the airspaces beyond the terminal bronchiole become permanently enlarged.

Signs and symptoms:

PROMINENT, PROGRESSIVE DYSPNEA is the main complaint, but — unlike chronic bronchitis — cough and sputum are minimal. Patients often develop a BARREL CHEST (from chronic air trapping), breathe with pursed lips, have a thin body habitus, and use extra (accessory) muscles to breathe. Cyanosis is uncommon here. This picture — thin, breathless, working hard but not blue — earns the nickname the "PINK PUFFER."

The lab finding that distinguishes it from chronic bronchitis:

DLCO is MARKEDLY REDUCED — below 60% — because here the gas-exchange surface itself has been destroyed, not just obstructed. TLC (total lung capacity) is above 120%, reflecting all that trapped air.

Treatment:

• Smoking cessation — the single most important intervention
• Bronchodilators (LABA + LAMA)
• Pulmonary rehabilitation
• Vaccinations
• Supplemental oxygen for hypoxemia, target 88–92%
• Alpha-1 antitrypsin augmentation therapy in patients who are deficient
• Lung volume reduction surgery or transplant in selected cases

Emphysema isn't one uniform disease — where the damage happens and why it happens split it into three types.

Asthma is reversible airway hyperresponsiveness — a combination of bronchospasm, inflammation, and mucus that narrows the airway and then, unlike COPD, can open back up again. That REVERSIBILITY is what separates it from COPD.

Two flavors of asthma — extrinsic (allergic) vs intrinsic (non-allergic):

How an attack builds, in order:

1. An allergen or irritant sets off immune activation, which causes MAST CELL DEGRANULATION — mast cells rupture and release two kinds of chemical messengers: vasoactive mediators (which dilate blood vessels and make capillaries leakier) and chemotactic mediators (which call in more immune cells).
2. EARLY PHASE (minutes): histamine, prostaglandins, and leukotrienes released in that first wave cause the smooth muscle around the airway to contract, narrowing it — this happens within minutes.
3. LATE PHASE (several hours later): a second wave of cells — basophils, eosinophils, neutrophils, and memory T cells — arrives and keeps the bronchoconstriction and inflammation going.
4. With continued exposure, this becomes a self-feeding cycle: bronchospasm leads to acute inflammation, which leads to mucus accumulation, which leads to the alveoli over-inflating, which leads to erosion and fibrosis of the airway lining — ending in BRONCHIAL HYPERRESPONSIVENESS, where the airway overreacts to smaller and smaller triggers, and partial or total airway obstruction.

Signs and symptoms:

Shortness of breath, chest tightness, cough, EXPIRATORY WHEEZING, PROLONGED EXPIRATION, tachypnea (fast breathing), tachycardia (fast heart rate), excess mucus, decreased alertness, and pulsus paradoxus (blood pressure that drops more than normal during inhalation).

Why wheezing happens: air is turbulent as it's forced through bronchioles that are narrowed by both spasm and mucus, and that turbulence during EXHALATION is what makes the sound. It's loudest on expiration because breathing out already raises the pressure inside the chest, which squeezes the already-narrow airways even further.

The two-stage blood gas story — this is the highest-yield, most counterintuitive part of this unit:

During an attack, the arterial blood gas (ABG) doesn't just get steadily worse in one direction — it flips, and the flip is a warning sign, not an improvement.

1. EARLY in an attack: the obstruction makes her breathe fast (HYPERVENTILATION). Breathing fast blows off more CO2 than normal, so PaCO2 falls and blood pH rises — this is RESPIRATORY ALKALOSIS. At this stage the numbers can almost look reassuring, because she's still moving enough air to over-breathe.
2. LATE in an attack, if it isn't controlled: the obstruction, air trapping, and sheer muscle fatigue catch up with her. She can no longer move enough air per breath (reduced tidal volume) — this is HYPOVENTILATION — so CO2 starts climbing again, and PaCO2 rises above normal. This is RESPIRATORY ACIDOSIS.

Diagnostics:

• SPIROMETRY first, then repeated AFTER a bronchodilator to test whether the obstruction is reversible
• PEAK FLOW METER for home self-monitoring — day-to-day variability above 20% over a week is consistent with asthma
• CHEST X-RAY is usually NORMAL in asthma
• METHACHOLINE CHALLENGE TEST — the GOLD STANDARD when someone's symptoms suggest asthma but their spirometry looks normal. Escalating doses of methacholine are given until FEV1 drops 20%; a positive test is a PC20 below 8 mg/mL (8–16 is borderline), and a NEGATIVE test rules asthma out. SABAs, LABAs, and anticholinergics must be held beforehand, because they can cause a false-normal result.

Stepwise pharmacologic management — treatment escalates as control worsens:

• EVERY asthma patient should have a SABA (albuterol) on hand
• Step UP treatment if control isn't good enough, step DOWN if it's been well controlled for at least 3 months
• Consult a specialist starting at step 4; consider it at step 3
• EXERCISE-INDUCED BRONCHOSPASM is a marker that asthma control is INADEQUATE, not just an expected quirk
• Chronic high-dose inhaled corticosteroids carry real side effects: osteoporosis, growth failure in children, glaucoma, cataracts, immune suppression, and HPA axis suppression

The two first-line drugs, in order of what happens first:

1. RAPID-ACTING BETA-2 AGONIST BY NEBULIZER — albuterol 2.5 mg, given at an acute frequency (for example, every 20 minutes for three doses). This works fast, which is why it comes first.
2. CORTICOSTEROID (oral or IV) — reduces the underlying inflammation. It is NOT rapid-acting, but it's started early anyway, because the inflammation needs to start coming down before the fast-acting drug's effect wears off.

You judge whether the SABA is working by ASSESSING BREATH SOUNDS — not just by how the patient feels, since a silent chest can be quietly worse than a wheezing one (see the two-stage ABG story). Antibiotics, arterial blood gases, and IV fluids all come AFTER airway management — they don't take priority over getting air moving.

Peak flow action plan — what to do based on how close her breathing is to her personal best:

What she should be teaching every asthma patient:

• RECOGNIZE EARLY SYMPTOMS of an exacerbation, so treatment starts before it becomes an emergency
• IDENTIFY AND AVOID TRIGGERS — this is the primary prevention strategy, more foundational than any medication
• Follow a written ASTHMA ACTION PLAN, and know the mild, moderate, and severe zones and how to adjust doses in each
• TAKE MEDICATIONS AS PRESCRIBED — controller medications daily, not only when symptoms show up
• Demonstrate PROPER INHALER TECHNIQUE and how to use a spacer
• Know when to call the provider or go to the emergency department — for example, PROGRESSIVELY INCREASING RESCUE INHALER USE is a red flag that control is slipping
• Get VACCINATED (influenza, pneumococcal, COVID)
• REGULAR EXERCISE is encouraged, not avoided — being able to talk in full sentences during activity is a good sign the intensity is safe
• Monitor peak flow at home and keep a record of the readings

One thing worth knowing about risk: asthma mortality rises sharply with age — 29.5 deaths per million in people above age 65, versus 2.7 per million in children. And one drug class is an outright no: BETA BLOCKERS ARE CONTRAINDICATED in asthma, because they carry a risk of triggering fatal bronchoconstriction.

ILD is an injury that heals badly: instead of clean repair, the body lays down scar tissue in the interstitium — the tissue AROUND the alveoli — so oxygen can't cross it and the lungs can't stretch.

How it develops, step by step:

1. Lung injury triggers an abnormal healing response.
2. FIBROBLAST ACTIVATION and COLLAGEN DEPOSITION follow — this is scar-tissue-building — and the interstitium thickens.
3. That thickening causes two separate consequences: STIFF LUNGS (reduced compliance, so it takes more effort to expand them) and a THICKENED ALVEOLAR-CAPILLARY MEMBRANE (a longer, harder path for gas to cross).
4. Put together, the result is a RESTRICTIVE pattern (small stiff lungs) plus IMPAIRED DIFFUSION (gas struggles to cross even when air does get in).
5. This is IRREVERSIBLE — once scar tissue forms, it cannot be undone.

Risk factors:

Occupational and environmental toxins (ASBESTOS, silica), SMOKING, certain MEDICATIONS, AUTOIMMUNE DISEASE (rheumatoid arthritis, systemic sclerosis), genetic predisposition, older age, and male sex. When no cause can be found, it's called idiopathic interstitial pneumonia.

Drug-induced ILD — the drugs to know:

METHOTREXATE, AMIODARONE, nitrofurantoin, bleomycin, BETA BLOCKERS, and statins.

Complications — the downstream chain:

PULMONARY HYPERTENSION leads to COR PULMONALE (right heart strain from lung disease), which leads to RESPIRATORY FAILURE.

Treatment — since the scarring itself can't be reversed, the goals are to slow progression and relieve symptoms:

• Corticosteroids
• Immunosuppressives (azathioprine, mycophenolate, cyclophosphamide)
• ANTIFIBROTICS — pirfenidone and nintedanib
• Treating GERD, since reflux worsens lung damage
• Oxygen therapy
• Pulmonary rehabilitation
• LUNG TRANSPLANTATION in advanced disease

What you'll find on exam:

• PROGRESSIVE DYSPNEA ON EXERTION
• DRY, NON-PRODUCTIVE COUGH
• FINE BIBASILAR INSPIRATORY CRACKLES — the classic auscultatory (listening) finding
• CLUBBING OF THE FINGERS — from chronic low oxygen
• Fatigue; occasional chest discomfort
• Cyanosis and weight loss as the disease progresses
• Reduced chest expansion; tachypnea

Diagnostic findings:

• IMAGING (chest X-ray and CT): bilateral reticular opacities, ground-glass opacities, and — in advanced disease — HONEYCOMBING
• PFTs: a RESTRICTIVE pattern — reduced lung volumes, reduced TLC, a normal or increased FEV1/FVC ratio, and REDUCED DLCO
• Labs: autoimmune markers; mildly elevated ESR and CRP
• Lung biopsy when needed to confirm the specific type

ILD versus sarcoidosis — how to tell them apart when both cause lung symptoms: